These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26941185)

  • 1. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Crit Rev Toxicol; 2016 Jul; 46(6):477-89. PubMed ID: 26941185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
    Arnaiz JA; Carné X; Riba N; Codina C; Ribas J; Trilla A
    Eur J Clin Pharmacol; 2001 Apr; 57(1):89-91. PubMed ID: 11372600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
    McNaughton R; Huet G; Shakir S
    BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
    Aronson JK
    Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WITHDRAWN--a resource for withdrawn and discontinued drugs.
    Siramshetty VB; Nickel J; Omieczynski C; Gohlke BO; Drwal MN; Preissner R
    Nucleic Acids Res; 2016 Jan; 44(D1):D1080-6. PubMed ID: 26553801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawn medicines included in the essential medicines lists of 136 countries.
    Charles O; Onakpoya I; Benipal S; Woods H; Bali A; Aronson JK; Heneghan C; Persaud N
    PLoS One; 2019; 14(12):e0225429. PubMed ID: 31791048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.
    Clarke A; Deeks JJ; Shakir SA
    Drug Saf; 2006; 29(2):175-81. PubMed ID: 16454545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision.
    Craveiro NS; Lopes BS; Tomás L; Almeida SF
    Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
    Aagaard L; Hallgreen CE; Hansen EH
    Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs.
    Kocadal K; Saygi S; Alkas FB; Sardas S
    North Clin Istanb; 2019; 6(2):196-202. PubMed ID: 31297490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.